Sorafenib-induced premalignant and malignant skin lesions.
about
Improved survival with vemurafenib in melanoma with BRAF V600E mutationRAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.Chemotherapy and skin reactions.Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.Sorafenib in melanoma.Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.Cutaneous effects of BRAF inhibitor therapy: a case series.Vemurafenib for the treatment of melanoma.Dermatological adverse events from BRAF inhibitors: a growing problem.Molecularly targeted therapies for melanoma.Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.Skin toxicity of targeted cancer agents: mechanisms and intervention.BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management.RAS Proteins and Their Regulators in Human Disease.Sorafenib-associated facial acneiform eruption.Targeted Therapy for Medullary Thyroid Cancer: A Review.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
P2860
Q24631953-2EBB3605-882B-470B-A79C-8FEC8ABFE379Q35721081-627E304B-5CD1-4FC0-8102-903BEBAFD374Q35898282-BAEAE236-EB01-48DC-8BDE-E0FB5C3E5E5EQ36641727-CDAC87EC-D9E0-4FBA-A6DD-B8EBF644EC2DQ36871242-D557456C-7CC8-4692-AFCD-96F47F6DE83FQ37990977-3EE4E390-2EEF-4D02-902D-9F7BF0031F40Q38036715-9E711BF8-254B-49C8-83FC-403B6D912A3CQ38049306-A2922BAE-04F2-46AD-AEA5-E967F9BA379AQ38055208-A20FA2CD-82F0-40EC-862E-8C5E2AD118EDQ38086762-986C413D-F20C-4AA5-A5D5-9818C03FD066Q38099392-4585E537-4242-43A5-A3F5-1EA77E6913C4Q38123513-C1D83AC3-9B6F-4BCB-9C33-E4BA77CE2AE7Q38125504-19F5FD4D-000E-45AF-9F35-0B2CE4070976Q38281838-567DBA61-6383-4705-AF75-6CB400DD81C4Q38425859-63C9469F-A572-455B-BED1-54A3FC513D72Q38764961-83F3195D-D911-4AC3-9C6E-439F36FD8222Q39407402-77164079-B855-4D8A-A06A-7D7B2BA40363Q41651222-5B79F6EE-95B0-4E2A-A950-1E222A2D2DC2Q49328959-3E9F0CA8-440A-48E8-8309-64C21002BBAFQ49887919-5C63C88B-8E98-45D4-88D3-D1C71737031F
P2860
Sorafenib-induced premalignant and malignant skin lesions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sorafenib-induced premalignant and malignant skin lesions.
@en
Sorafenib-induced premalignant and malignant skin lesions.
@nl
type
label
Sorafenib-induced premalignant and malignant skin lesions.
@en
Sorafenib-induced premalignant and malignant skin lesions.
@nl
prefLabel
Sorafenib-induced premalignant and malignant skin lesions.
@en
Sorafenib-induced premalignant and malignant skin lesions.
@nl
P2093
P2860
P1476
Sorafenib-induced premalignant and malignant skin lesions.
@en
P2093
David J Stewart
Philip R Cohen
Victoria L Williams
P2860
P304
P356
10.1111/J.1365-4632.2010.04822.X
P577
2011-04-01T00:00:00Z